Mission appoints chief business officer
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, has named Dr Paul Wallace chief business officer. Dr Wallace was most recently executive vice-president and head of business development at Medivir, where he was also a member of the executive management team responsible for strategic and operational leadership, R&D portfolio management and investment planning.